Revenue Growth (YoY)
Higher than 18% of Healthcare sector peers
Updated 1078h ago
Sector Performance
18th percentileRARE
-2.4%
Sector Median
6.2%
Sector Avg
3.8%
Deep Analysis
Ultragenyx Pharmaceutical Inc. (RARE) has a Revenue Growth (YoY) of -2.4% as of May 2026.
This places RARE in the 18th percentile of the Healthcare sector, which has a median Revenue Growth (YoY) of 6.2% and a sector average of 3.8%. RARE's Revenue Growth (YoY) is 138.7% below the sector median, a significant divergence that warrants closer examination. In context: Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
Frequently Asked Questions
What does the Revenue Growth (YoY) tell investors about RARE?
Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
How is the Revenue Growth (YoY) calculated?
Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.
How does RARE's Revenue Growth (YoY) compare to its sector?
RARE's Revenue Growth (YoY) of -2.4% compares to a Healthcare sector median of 6.2%, placing it in the 18th percentile.
Who are RARE's closest peers by Revenue Growth (YoY)?
The closest Healthcare peers by Revenue Growth (YoY) include: TMO (6.2%), AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%).
The Formula
(Revenue_t - Revenue_t-4) / Revenue_t-4
Why It Matters
Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
Master RARE's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full RARE research report →RARE
-2.4%
Sector Median
6.2%
Sector Avg
3.8%
How RARE's Revenue Growth (YoY) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.